Patients With Treatment-Naïve CLL Treated With BTK Inhibition
This roundtable series assesses using Bruton kinase inhibitors in patients with chronic lymphocytic leukemia as first-line therapy, as discussed by key opinion leaders and participants at virtual live events.
Second Generation BTK Inhibitors Improve Survival in R/R CLL Setting
November 8th 2023In the second article of a 2-part series, William G. Wierda, MD, PhD, looks at the efficacy and safety outcomes with the second generation BTK inhibitor zanubrutinib for patients with relapsed/refractory chronic lymphocytic leukemia.
